Tagged with Biogen

China China Pharma Roundup: Sinopharm Tops Brand Value Rankings; Simcere Splashes $565M on Alzheimer’s Drug; Innovent-Ascentage Tie-Up A Sign of Biotech Deals to Come?

China The latest news from the Chinese pharmaceutical industry, including recent deals between domestic pharma giant Simcere and German biotech Vivoryon in Alzheimer’s; Innovent’s tie-up with Ascentage; Biogen’s USD 125 million midstage MS drug pact with InnoCare; and Everest Medicines’ partnership with social media giant Tencent. Sinopharm Tops Ranking of…

A New Era for Mental Health in Switzerland?

Switzerland A New Era for Mental Health in Switzerland?

Switzerland Mental health is a global crisis. 25 percent of the world’s population struggle with mental illness; and mental, neurological, and substance use disorders account for 11 percent of the total global disease burden according to data from the Healthy Brains Global Initiative (HBGI). Global mental healthcare costs are expected to…

Aducanumab Approval: Opening the Floodgates for a New Era of Alzheimer’s Treatment?

USA Aducanumab Approval: Opening the Floodgates for a New Era of Alzheimer’s Treatment?

USA With the US FDA’s controversial recent decision to approve Biogen and Eisai’s aducanumab – the first approval for a new Alzheimer’s disease (AD) drug since 2003 – PharmaBoardroom has raided its archives to bring key industry stakeholders’ takes on the significance of this decision and what it might mean for…

If the “Primary Endpoint” in an Alzheimer’s Study is Outcomes, Think Biogen + Spotify

USA If the “Primary Endpoint” in an Alzheimer’s Study is Outcomes, Think Biogen + Spotify

USA Taking the example of music’s effect on Alzheimer’s disease patients, John G Singer makes the case for a more holistic approach to healthcare; focusing less on the transformative potential of individual drugs and more on value as a stream of benefits delivered through a living system. Singer/songwriter Glen Campbell,…

Katharina Gasser – Managing Director, Biogen Switzerland

Switzerland Katharina Gasser – Managing Director, Biogen Switzerland

Switzerland Biogen Switzerland’s Dr med Katharina Gasser outlines how her affiliate navigated the COVID-19 pandemic from an organisational and communication perspective, the increasing importance being given to mental health by the Swiss government, and the reimbursement and market challenges facing Biogen in 2021 and beyond. 2020 saw a lot of…

Antonella Santuccione Chadha – CEO pro-bono, Women’s Brain Project & Head of Stakeholder Engagement for Alzheimer’s Disease, Biogen

Switzerland Antonella Santuccione Chadha – CEO pro-bono, Women’s Brain Project & Head of Stakeholder Engagement for Alzheimer’s Disease, Biogen

Switzerland Antonella Santuccione Chadha*, Head of Stakeholder Engagement for Alzheimer’s disease at Biogen and co-founder and CEO of the Women’s Brain Project, dives into the non-profit organization’s role in rethinking the way we look at sex and gender as a gateway to precision medicine. She explains how artificial intelligence (AI) is…

Swiss Pharma: Staying the Course

Switzerland Swiss Pharma: Staying the Course

Switzerland This article forms part of Healthcare & Life Sciences Review: Switzerland February 2021, a comprehensive up-to-date country report on the Swiss pharma market, featuring data snapshots, feature articles, exclusive interviews and more. Click here to download. Long heralded as an innovation powerhouse able to hold its own against the…

Biogen’s Swiss Head on Benefits of Diverse Experience & Building an Entrepreneurial Team

Switzerland Biogen’s Swiss Head on Benefits of Diverse Experience & Building an Entrepreneurial Team

Switzerland A trained physician with several years of practice under her belt, Katharina Gasser then moved into clinical research as an investigator before joining the pharma industry in 2005. Now head of Biogen’s Swiss affiliate and chair of the executive committee of industry association Interpharma, Gasser cites her diverse background as…

What Three Pharma Leaders Want to Share About Switzerland

Switzerland What Three Pharma Leaders Want to Share About Switzerland

Switzerland PharmaBoardroom highlights three of the most enterprising and dynamic pharma affiliate country managers working in Switzerland today and their strategies for success in one of the world’s most innovative nations. Henrik Asmussen, General Manager, Amgen Switzerland Danish national Henrik Asmussen, head of Amgen Switzerland since 2017, outlined the…

Aducanumab edges closer to Potential Approval: Next up, the Advisory Committee meeting

USA Aducanumab edges closer to Potential Approval: Next up, the Advisory Committee meeting

USA In his latest piece on Alzheimer’s Disease (AD) drug Aducanumab’s winding journey to market, Dr Neil Cashman looks forward to the US FDA Advisory Committee’s meeting on November 6 2020, what it means for that Aducanumab, and the impact on next-generation AD treatments. November 6 could prove to be…

Moving the Needle on Gender Diversity in Swiss Pharma Leadership

Switzerland Moving the Needle on Gender Diversity in Swiss Pharma Leadership

Switzerland While Switzerland has Europe’s second-highest proportion of women in the workforce, it trails global standards on gender diversity in boardrooms and in management positions. However, this situation is changing and two of Switzerland’s most important pharma affiliates are at the forefront of a new wave of diverse Swiss leadership teams.…

Katharina Gasser – Managing Director, Biogen Switzerland & Chair of the Executive Committee, Interpharma (October 2020)

Switzerland Katharina Gasser – Managing Director, Biogen Switzerland & Chair of the Executive Committee, Interpharma (October 2020)

Switzerland Biogen Switzerland’s Dr Katharina Gasser outlines how the company’s 100 percent commitment to neuroscience helps it to stand apart, why Switzerland will continue to play a vital role in Biogen’s global clinical research footprint, and some of the country’s market access and pricing challenges. Dr Gasser also highlights Biogen’s burgeoning…

1 2 3 4 … 6